Efter 35 dages behandling med Raptiva var antallet af patienter behandlet med efalizumab med positive priktestreaktioner på Candida signifikant reduceret i forhold til placebo gruppen.
After 35 days of treatment with Raptiva, the proportion of subjects treated with efalizumab with positive skin test reactions to Candida was significantly reduced compared with the placebo group.